Ayda Esmaeili, Zahra Niazkhani, Khadijeh Makhdoomi, Iraj Mohebbi, Javad Aghazadeh-Attari, Ebrahim Hassani, Seyed Jalil Mousavi, Naser Gharebaghi, Rahim Nejadrahim, Mohammad Mirza-Aghzadeh, Aysan Esmaeili, Mojgan Cheshmekaboodi, Yasaman Nader-Babaei, Habibollah Pirnejad
OBJECTIVES: The prevalence, types, severity, risk ratings, and common pairs of involved drugs, and the most important potential drug-drug interactions (pDDIs) in coronavirus disease 2019 (-COVID-19) deceased cases were evaluated. MATERIALS AND METHODS: We reviewed the medical records of 157 confirmed COVID-19 deceased cases hospitalized in 27 province-wide hospitals. Patients' demographics and clinical data (including comorbidities, vital signs, length of in-hospital survival, electrocardiograms (ECGs), medications, and lab test results) were extracted...
October 25, 2023: International Journal of Clinical Pharmacology and Therapeutics